Resmetirom and Semaglutide in MASH: Who, when and how to monitor?
This episode of Talk Liver to Me explores the practical use of resmetirom and semaglutide in MASH, based on the 2026 EASL–EASD–EASO Guidance. Experts discuss who may benefit from treatment, when to initiate therapy, and how to monitor response and efficacy in clinical practice.
Host: Debbie Shawcross (EASL)
Guests: Andreea Ciudin (EASO), Amalia Gastaldelli (EASD), Frank Tacke (EASL)
Prefer to listen on the go? This episode is also available on the following streaming platforms:
Talk Liver To Me is supported by Boehringer Ingelheim, GSK, IPSEN and Opella. Boehringer Ingelheim, GSK, IPSEN and Opella have had no input to the content of this programme.
This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL.
COI - Speakers have reported the following potential conflicts of interest: Debbie Shawcross: None Frank Tacke: Received grants from Gilead, MSD; Is a consultant for Astra Zeneca, Gilead, Novonordisk, Magridal; Has given sponsored lectures for Gilead, Ipsen, Mirum, GSK, MSD, Falk Andreea Ciudin: None Amalia Gastaldelli: Served as consultant on advisory boards for Boehringer Ingelheim, Madrigal, Merck Sharp & Dohme, Novo Nordisk, Regeneron; Has received speaker honorarium travel support or other educational fees from Boehringer Ingelheim, Merck Sharp & Dohme, Novo Nordisk, Madrigal, Mercodia.
EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.
